ADVERTISEMENT
Conference Coverage
The Case Against Antibody Drug Conjugates for Patients With Lung Cancers
Corey Langer, MD
05/15/2024
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, Abramson Cancer Center, Philadelphia, Pennsylvania, argued that antibody drug conjugates are not ready to replace TROP-2 inhibitors as the standard of care for patients with lung cancers.
Source:
Langer C. Debate: ADCs: The new emperor or the emperor’s new clothes. Presented at Great Debates & Updates in Lung Cancer; April 27-28, 2024; New York, NY.
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement